Compare Johnson & Johnson (JNJ) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Total World Stock Index Fund ETF — how do they compare? Johnson & Johnson trades at $250.16 (market cap $598.96B), while Vanguard Total World Stock Index Fund ETF trades at $155.78. The key difference: Johnson & Johnson pays a 2.15% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| JNJ | VT | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Broad Market / Factor |
52-Week High | $267.24 | $159.35 |
52-Week Low | $164.36 | $128.41 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VT trades at $154.29, down 0.32% on the day, with technical indicators signaling a bearish trend amid neutral oscillators. The ETF's broad global diversification and low expense ratio of 0.06% are key strengths, though financial ratios are not disclosed in the provided data. Recent news highlights comparisons with competing international ETFs, emphasizing VT's comprehensive market exposure.
The outlook remains cautious due to bearish technical signals and competitive pressures from lower-cost alternatives. Risks include expense ratio disadvantages versus peers and global market volatility. Analyst sentiment is mixed, with ongoing debates about optimal international ETF selection influencing investor positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
